|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE
10/22/2012 9:19:40 AM
SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE. The Phase 2a study demonstrated that markers of immune system hyperactivation driving HIV disease progression can be rapidly and effectively reduced by AV-HALTs, resulting in a proportional restoration of immune system damage. “It has been more than thirty years since the first AIDS cases were reported,” said Franco Lori, MD and CEO of ViroStatics. “Since these first reports, the field has made great advances against HIV. Yet, an unmet medical need remains – how to directly reduce the immune system’s excessive response to the virus, a response that paradoxically becomes harmful over time.”
|
|
|
|
|
|
|
|
|
|
|